Bacteria compete not only by killing rivals but also by disrupting their developmental programs, yet the molecular basis of such nonlethal interference remains largely unknown. Here, we report tamastrepamides, a family of alkylproline‐containing cyclodepsipeptides from Streptomyces sp. HL19 that function as interspecific effectors by selectively downregulating transcription of the master developmental regulator bldD . The horizontally acquired tam biosynthetic gene cluster is conspicuously enriched in rare TTA codons, functionally coupling its expression to the developmentally regulated tRNA Leu (UAA) encoded by bldA . Tamastrepamide A arrests sporulation and diminishes secondary metabolite production in diverse actinomycetes without inhibiting vegetative growth, thereby chemically phenocopying a Δ bldD mutant. Promoter‐specific reporter assays demonstrate that tamastrepamide A reduces bldD promoter activity, while the producer strain is intrinsically insensitive to this effect. Production of tamastrepamides strictly depends on the functionally specialized tRNA Leu (UAA), revealing a self‐contained regulatory circuit in which a developmentally gated metabolite disables the same developmental program in neighboring competitors. These findings illustrate an ecological strategy in which a developmentally regulated biosynthetic pathway produces a diffusible metabolite that interferes with the sporulation program of competing actinomycetes.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: